Natera (NTRA) Raised to Sell at BidaskClub

BidaskClub upgraded shares of Natera (NASDAQ:NTRA) from a strong sell rating to a sell rating in a research report released on Wednesday morning.

Several other analysts have also recently weighed in on NTRA. Cowen reaffirmed a buy rating and set a $12.00 price objective on shares of Natera in a research report on Thursday, December 21st. Zacks Investment Research raised Natera from a sell rating to a hold rating in a research report on Wednesday, January 10th. Craig Hallum initiated coverage on Natera in a research report on Monday, April 9th. They issued a buy rating and a $16.00 price target on the stock. Finally, ValuEngine raised Natera from a sell rating to a hold rating in a research report on Wednesday. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the stock. The company presently has an average rating of Hold and an average price target of $14.80.

Natera stock opened at $10.29 on Wednesday. The company has a current ratio of 1.37, a quick ratio of 1.29 and a debt-to-equity ratio of -7.05. The company has a market cap of $551.04, a price-to-earnings ratio of -4.29 and a beta of 2.10. Natera has a fifty-two week low of $7.49 and a fifty-two week high of $14.76.



Natera (NASDAQ:NTRA) last posted its quarterly earnings data on Tuesday, March 13th. The medical research company reported ($0.73) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.46) by ($0.27). The firm had revenue of $53.80 million for the quarter, compared to the consensus estimate of $56.83 million. Natera had a negative net margin of 64.61% and a negative return on equity of 357.12%. analysts forecast that Natera will post -1.85 earnings per share for the current year.

Several institutional investors and hedge funds have recently modified their holdings of the company. Macquarie Group Ltd. boosted its position in shares of Natera by 11.8% in the 4th quarter. Macquarie Group Ltd. now owns 1,494,152 shares of the medical research company’s stock worth $13,432,000 after purchasing an additional 157,159 shares in the last quarter. Geode Capital Management LLC boosted its position in shares of Natera by 4.0% in the 4th quarter. Geode Capital Management LLC now owns 352,850 shares of the medical research company’s stock worth $3,172,000 after purchasing an additional 13,708 shares in the last quarter. Tygh Capital Management Inc. boosted its position in shares of Natera by 5.3% in the 4th quarter. Tygh Capital Management Inc. now owns 228,268 shares of the medical research company’s stock worth $2,052,000 after purchasing an additional 11,535 shares in the last quarter. Schwab Charles Investment Management Inc. boosted its position in shares of Natera by 13.3% in the 4th quarter. Schwab Charles Investment Management Inc. now owns 154,467 shares of the medical research company’s stock worth $1,389,000 after purchasing an additional 18,187 shares in the last quarter. Finally, Citadel Advisors LLC boosted its position in shares of Natera by 11.0% in the 4th quarter. Citadel Advisors LLC now owns 112,830 shares of the medical research company’s stock worth $1,014,000 after purchasing an additional 11,199 shares in the last quarter. 67.14% of the stock is currently owned by hedge funds and other institutional investors.

WARNING: This piece of content was originally published by Dakota Financial News and is the property of of Dakota Financial News. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of US and international copyright law. The correct version of this piece of content can be viewed at https://dakotafinancialnews.com/2018/04/14/natera-ntra-raised-to-sell-at-bidaskclub.html.

About Natera

Natera, Inc, a diagnostics company, provides preconception and prenatal genetic testing services. It primarily offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus typically with a blood draw from the mother; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrier's children; and Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.

Analyst Recommendations for Natera (NASDAQ:NTRA)

Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply